Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 12/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022509 | 0.92 | HMGCR (0.45) | HMGCR | |
| SCHEMBL1347123 | 0.92 | HMGCR (0.49) | HMGCR | |
| SCHEMBL20699721 | 0.91 | HMGCR (0.48) | HMGCR | |
| SCHEMBL1978777 | 0.89 | HMGCR (0.48) | HMGCR | |
| SCHEMBL14243679 | 0.87 | HMGCR (0.47) | HMGCR | |
| SCHEMBL20699715 | 0.86 | HMGCR (0.48) | HMGCR | |
| SCHEMBL2368051 | 0.85 | HMGCR (0.53) | HMGCR | |
| SCHEMBL2368048 | 0.85 | HMGCR (0.53) | HMGCR | |
| SCHEMBL8511795 | 0.84 | HMGCR (0.46) | HMGCR | |
| SCHEMBL13428668 | 0.83 | HMGCR (0.54) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759518-B2 | Intermediates for the preparation of HMG CoA reductase inhibitors and processes for the preparation thereof | CADILA HEALTHCARE LIMITED (IN) | 2014-06-24 | — | — | US | claimed |
| US-20130158263-A1 | INTERMEDIATES FOR THE PREPARATION OF HMG COA REDUCTASE INHIBITORS AND PROCESSES FOR THE PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2013-06-20 | — | — | US | claimed |
| WO-2011104725-A2 | HMG-COA REDUCTASE INHIBITORS AND PROCESS FOR THE PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-09-01 | — | — | WO | claimed |
| US-8759518-B2 | Intermediates for the preparation of HMG CoA reductase inhibitors and processes for the preparation thereof | CADILA HEALTHCARE LIMITED (IN) | 2014-06-24 | — | — | US | disclosed |
| US-20130158263-A1 | INTERMEDIATES FOR THE PREPARATION OF HMG COA REDUCTASE INHIBITORS AND PROCESSES FOR THE PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2011104725-A2 | HMG-COA REDUCTASE INHIBITORS AND PROCESS FOR THE PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158263-A1 | INTERMEDIATES FOR THE PREPARATION OF HMG COA REDUCTASE INHIBITORS AND PROCESSES FOR THE PREPARATION THEREOF | HMGCR, DHCR7, NR1H3 | HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.